Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States

Campos‐Varela, Isabel; Dodge, Jennifer L.; Berenguer, Marina; Adam, René; Samuel, Didier; Benedetto, Fabrizio Di; Karam, Vincent; Belli, Luca; Duvoux, Christophe; Terrault, Norah A.

doi:10.1097/tp.0000000000003107

Cited by 27 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 However, a recent study combining registry data from the United States and Europe showed that HCV decreased as an indication for LT for HIV-infected patients (from 76% to 52%) between 2008 and 2015, but the proportion of LTs performed in HIV-infected patients remained unchanged. 8 Whether an increasing burden of end-stage liver disease due to NASH and ALD, as seen in HIV-uninfected patients, is occurring in PLWH is not known. We aimed to evaluate changes in indications for LT among persons with and without HIV infection in the United States from 2008 to 2018, with a focus on temporal trends in nonviral indications for LT in HIV-infected patients, and to evaluate graft and patient outcomes during the study period.…”

Section: Ajt 1 | Introductionmentioning

confidence: 99%

Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus

Campos‐Varela

Dodge

Terrault

et al. 2021

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

We evaluated whether indications for liver transplantation (LT) have changed among people with/without human immunodeficiency virus (HIV) infection and compared LT outcomes and trends by HIV serostatus. LT recipients (2008LT recipients ( -2018 from the United Network for Organ Sharing and Organ Procurement and Transplantation Network (UNOS/OPTN) were identifed. Among 62 195 LT recipients, 352 (0.6%)were HIV-infected. The proportion of HIV-infected patients increased over time (P trend = .001), as did the number of transplant centers performing LT for HIV-infected recipients; average annual percentage change of 9.2% (p < .001). Nonviral causes became the leading indication in 2015 for HIV-uninfected and in 2018 for HIV-infected (P trend < .001). Three-year cumulative patient survival rates were 77.5%, for HIVinfected and 84.6%, for HIV-uninfected (p = .15). Over time, graft and patient survival rates improved for both HIV-infected and uninfected (p < .001). Among HCV-infected LT recipients, 3-year patient survival rates were 72.5% for HIV-infected and 81.8% for HIV-uninfected (p = .02). However, in a subanalysis restricted to 2014-2018, differences in graft and patient survival by HIV serostatus were no longer observed (3-year patient survival rates were 81.2% for HIV-infected and 86.4% for HIV-uninfected, p = .34). In conclusion, in the United States, nonviral liver disease is now the leading indication for LT in HIV-infected patients, and posttransplant outcomes have improved over time.

show abstract

Section: Ajt 1 | Introductionmentioning

confidence: 99%

Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus

Campos‐Varela

Dodge

Terrault

et al. 2021

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“… 14 AASLD does not have an official definite scoring system, and the Organ Procurement and Transplantation Network (commonly referred to as OPTN) is a unique system for transplantation adopted in the USA. 4 , 18 Therefore, we only evaluated the systematic training effect of LI-RADS in this study. In our study, the interobserver agreements of all radiologists for the LR category were increased after systematic training.…”

Section: Discussionmentioning

confidence: 99%

Systematic Training of Liver Imaging Reporting and Data System Magnetic Resonance Imaging v2018 can Improve the Diagnosis of Hepatocellular Carcinoma for Different Radiologists

Ren

Zhang

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

What is LI-RADS ® ?The Liver Imaging Reporting And Data System (LI-RADS) is:• A comprehensive system for standardizing the terminology, technique, interpretation, reporting, and data collection of liver imaging • A dynamic document, to be expanded and refined as knowledge accrues and in response to user feedback • Designed to improve communication, patient care, education, and research • Supported and endorsed by the American College of Radiology (ACR) • Developed by a multidisciplinary, international consortium of diagnostic and interventional radiologists, hepatobiliary surgeons, hepatologists, and hepatopathologists. Contributors include academic and community physicians as well as members in training. Overview Ultrasound LI-RADS ® CEUS LI-RADS ® CT/MRI Diagnostic LI-RADS ® CT/MRI Treatment Response LI-RADS ® LI-RADS ® v2018 CT/MRI Core Diagnostic Algorithm Treatment Response Last Viewed What's New in LI-RADS ® v2018? Revised, simplified definition of threshold growth• Threshold growth definition was simplified to: ≥ 50% size increase of a mass in ≤ 6 months.• Rationale: simplicity; achieve concordance with definitions advocated by AASLD and OPTN.• AASLD, OPTN, and LI-RADS now have the same definition for threshold growth. ⚠️Note: the following no longer meet criteria for TG but are considered subthreshold growth:• New ≥ 10 mm observations in ≤ 24 months • ≥ 100% size increase on imaging exams > 6 months apart Revised, simplified criteria for LR-5:• LR-5 criteria were revised to match those advocated by AASLD.• The -g and -us designations were eliminated for simplicity.• New LR-5 criteria are listed below and summarized in Diagnostic Table (page 8): Size Criteria Comments 10-19 mm Nonrim APHE AND • Nonperipheral "washout" Does not provide exception points for liver transplantation in USA Nonrim APHE AND both of the following: • Nonperipheral "washout" • Enhancing "capsule" Equivalent to OPTN 5A Nonrim APHE AND • Threshold growth* Equivalent to OPTN 5A-g ≥ 20 mm Nonrim APHE AND one or more of following: • Nonperipheral "washout" • Enhancing "capsule" • Threshold growth* Equivalent to OPTN 5B or 5X * Note -apply v2018 definition of threshold growth: ≥ 50% size increase of a mass in ≤ 6 months • Rationale: simplicity; closer concordance with AASLD and OPTN criteria. • LI-RADS and AASLD now have identical criteria for definite HCC. • LI-RADS and OPTN now have almost identical criteria for HCC, with one exception (below). ⚠️ Exception: 10-19 mm + APHE + nonperipheral "washout" = LR-5, but does not meet OPTN Class 5 criteria v2018 also includes clarifications, corrections, new FAQs, and some formatting changes. Most of these are in response to user feedback since v2017 release. What's New 4 LI-RADS ® v2018 CT/MRI Core Diagnostic Algorithm Treatment Response Last ViewedWhy is an update needed in 2018?The LI-RADS mission and long-term vision is to unify HCC diagnostic imaging criteria. Recently, a critical milestone was achieved with integration of LI-RADS into the American Association for the Study of Liver Diseases ...

show abstract

“…The increasing number of recipients enabled study of the outcome and/or evolution of LT in large patient populations ( Table 1). The place of LT in the treatment of acute liver failure, alcoholic cirrhosis, HBV/HDV/ HCV related cirrhosis, HIV infected patients, NASH, primary biliary cholangitis, autoimmune hepatitis were examined [14][15][16][17][18][19][20][21][22][23][24]. A hepatocellular cancer study focused on the value of locoregional therapies and the impact of vascular invasion on outcome after transplantation [25,26].…”

Section: Large Disease-specific Studiesmentioning

confidence: 99%

What did the European Liver Transplant Registry bring to liver transplantation?

et al. 2020

Self Cite

View full text Add to dashboard Cite

Since its foundation in 1985, the European Liver Transplant Registry has evolved to become an important tool to monitor the liver transplantation activity in Europe. The vast amount of data collected on 169 473 liver transplantations performed in 153 238 recipients has also resulted in scientific publications. Without doubt, several of these have influenced the daily practice of liver transplantation. This paper gives an overview of the development, the functioning, and the scientific activity of the European Liver Transplant Registry during more than three decades. Indeed, it can be said that the registry helped to advance the practice of liver transplantation not only in Europe but also worldwide.

show abstract

Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States

Cited by 27 publications

References 23 publications

Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus

Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus

Systematic Training of Liver Imaging Reporting and Data System Magnetic Resonance Imaging v2018 can Improve the Diagnosis of Hepatocellular Carcinoma for Different Radiologists

What did the European Liver Transplant Registry bring to liver transplantation?

Contact Info

Product

Resources

About